Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM).
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Hussein Abdul-Hassan Tawbi, Rodabe Navroze Amaria, Isabella Claudia Glitza, Denai Milton, Wen-Jen Hwu, Sapna Pradyuman Patel, Michael K.K. Wong, Cassian Yee, Scott Eric Woodman, Jennifer Leigh McQuade, Patrick Hwu, Karen Mae Perdon, Michael Shephard, Elizabeth M. Burton, Jennifer Ann Wargo, Michael A. Davies
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2892285167